All IndicationsMetabolic & EndocrinePhase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 2Phase 2Phase 2
⚡
Obesity
8
Companies
12
Drug Programs
6
Phase 3
0
Upcoming PDUFAs
Competitors
RHHBY
Roche Holding AG
RO7204239
LLY
Eli Lilly and Company
Retatrutide
NVO
Novo Nordisk A/S
Semaglutide 1.0 mg
LLY
Eli Lilly
retatrutide
MTVA
MetaVia Inc.
DA-1726
SNY
Sanofi
rimonabant (SR141716)
SNY
Sanofi
SR147778
IONS
Ionis Pharmaceuticals, Inc.
ISIS-FGFR4RX
SKYE
Skye Bioscience, Inc.
Nimacimab injection
LLY
Eli Lilly
Unknown obesity drug
AMGN
Amgen
MariTide
NVO
Novo Nordisk
liraglutide
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| RHHBY Roche Holding AG | RO7204239 | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | Retatrutide | Phase 3 | — | — | — |
| NVO Novo Nordisk A/S | Semaglutide 1.0 mg | Phase 3 | — | — | — |
| LLY Eli Lilly | retatrutide | Phase 3 | — | — | — |
| MTVA MetaVia Inc. | DA-1726 | Phase 3 | — | — | — |
| SNY Sanofi | rimonabant (SR141716) | Phase 3 | — | — | — |
| SNY Sanofi | SR147778 | Phase 2 | — | — | — |
| IONS Ionis Pharmaceuticals, Inc. | ISIS-FGFR4RX | Phase 2 | — | — | — |
| SKYE Skye Bioscience, Inc. | Nimacimab injection | Phase 2 | — | — | — |
| LLY Eli Lilly | Unknown obesity drug | — | — | — | — |
| AMGN Amgen | MariTide | — | — | — | — |
| NVO Novo Nordisk | liraglutide | — | — | — | — |
Development Stage Distribution
Unknown
3
Phase 3
6
Phase 2
3
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.